logo
Loading...
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease

Medicine and Health

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease

G. Pagano, K. I. Taylor, et al.

This exploratory analysis of the PASADENA phase 2 study highlights prasinezumab's potential as a disease-modifying therapy for early-stage Parkinson's disease. Although the primary endpoint wasn't achieved, findings suggest that prasinezumab may significantly slow motor sign progression in rapidly progressing patients. The research was conducted by prominent authors in the field.... show more
Citation Metrics
Citations
109
Influential Citations
1
Reference Count
16
Citation by Year

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny